Home Stocks PALI Palisade Bio Inc (NASDAQ: PALI) Healthcare · Biotechnology
$0.94 −0.07 (−6.93%)
Last close · Nov 18, 2026 · NASDAQ USD
The Quantellect read. PALI fell 6.93% in the Nov 18 session to $0.94, which is 66.4% below its 52-week high of $2.80. Eight active firms cover the stock as of Nov 19, 2026; eight active firms with targets average $9.63 over 12 months. Descriptive summary of the data on this page, not a recommendation.
Momentum Neutral RSI (14) 39.8 (overbought above 70, oversold below 30)
SMA 10 — SMA 20 — SMA 50 — SMA 200 —
Price details unavailable for this range. ×
Chart loads when this section enters view.
Dated chart events require JavaScript on this compact chart. Open the full chart for dated events .
Text price and event history 6M plotted price range (ET) Range 6M First date — Last date — Open — High — Low — Close — Volume — Plotted bars 0
Plotted OHLCV bars No price bars are available for this range.
Event records Event records load after the price chart.
Split-adjusted daily prices · Price as of —
Initial 6M price range summary Range 6M First close — Last close — High — Low — Volume —
Open $1.00 Nov 18, 2026 session
Previous close $1.01 Nov 17, 2026 close
Day range $0.94 – $1.01 Nov 18, 2026 session
52-week range $0.94 – $2.80 Through Nov 18, 2026
Volume 5.45M Nov 18, 2026 session
Average volume (30 calendar days, 0 sessions) — Through Nov 18, 2026
Market cap $202.15M
P/E (TTM) 1.2
Forward P/E —
EPS (TTM) stale vendor snapshot —
Dividend yield data unavailable —
Beta (5-year monthly vs SPY) —
Price history PALI · NASDAQ · USD
Split-adjusted · volume in shares
Price history unavailable Retry
Notable price movement — · Notable price movement not available
Options flow — · Options flow not available
Q Score — · Q Score not available
Industry comparison — · Industry comparison not available
Upcoming events — · Upcoming events not available
Analyst consensus Buy
0 Strong Buy
8 Buy
0 Neutral
0 Sell
0 Strong Sell
Based on 8 active firms as of Nov 19, 2026 (365-day activity window)
12-month price targets (third-party analysts) Low $5.00
Average $9.63
High $25.00
As of Nov 19, 2026 across 8 active firms with targets. Targets are published by third-party analysts, not by Quantellect.
Full analyst forecast →
Earnings history EPS, last 8 quarters −15.00 −10.00 −5.00 0.00 FY ’24 Q1 ’25 Q2 ’25 Q3 ’25 FY ’25 Q1 ’26 Q2 ’26 Q3 ’26
Estimate Beat Miss Match
Fiscal period Est. Actual Result
Q3 2026 −$0.06 −$0.07 —
Q2 2026 −$0.05 −$0.05 —
Q1 2026 −$0.04 −$0.05 —
Annual 2025 −$0.03 −$0.30 —
Q3 2025 — −$0.38 —
Q2 2025 — −$0.58 —
Q1 2025 — −$0.47 —
Annual 2024 −$1.99 −$10.19 —
News and press releases News and press releases are not available.
All PALI news → Company profile Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States. Its lead clinical product candidate includes PALI-2108, which is in phase 1b clinical trial to treat patients with inflammatory bowel disease, including ulcerative colitis and Fibrostenotic Crohn's disease. The company has a research collaboration and license agreement with Giiant
CEO Mr. J. D. Finley
Headquarters Denver, CO, United States
Employees 14
IPO date Dec 20, 2006
Sector Healthcare
Industry Biotechnology Q Score — · Q Score not available
Upcoming events — · Upcoming events not available
Analyst consensus Buy
0 Strong Buy
8 Buy
0 Neutral
0 Sell
0 Strong Sell
Based on 8 active firms as of Nov 19, 2026 (365-day activity window)
12-month price targets (third-party analysts) Low $5.00
Average $9.63
High $25.00
As of Nov 19, 2026 across 8 active firms with targets. Targets are published by third-party analysts, not by Quantellect.
Full analyst forecast →
Earnings history EPS, last 8 quarters −15.00 −10.00 −5.00 0.00 FY ’24 Q1 ’25 Q2 ’25 Q3 ’25 FY ’25 Q1 ’26 Q2 ’26 Q3 ’26
Estimate Beat Miss Match
Fiscal period Est. Actual Result
Q3 2026 −$0.06 −$0.07 —
Q2 2026 −$0.05 −$0.05 —
Q1 2026 −$0.04 −$0.05 —
Annual 2025 −$0.03 −$0.30 —
Q3 2025 — −$0.38 —
Q2 2025 — −$0.58 —
Q1 2025 — −$0.47 —
Annual 2024 −$1.99 −$10.19 —
Company profile Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States. Its lead clinical product candidate includes PALI-2108, which is in phase 1b clinical trial to treat patients with inflammatory bowel disease, including ulcerative colitis and Fibrostenotic Crohn's disease. The company has a research collaboration and license agreement with Giiant
CEO Mr. J. D. Finley
Headquarters Denver, CO, United States
Employees 14
IPO date Dec 20, 2006
Sector Healthcare
Industry Biotechnology